Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CDC25A | P30304 | 6/20 | 0.32 |
| ▸ | CDC25B | P30305 | 6/20 | 0.32 |
| ▸ | CDC25C | P30307 | 5/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7509115 | 0.98 | PPARG (0.37) | PPARGMAPTCDC25ACDC25BCDC25C | |
| SCHEMBL451036 | 0.85 | — | — | |
| SCHEMBL7137786 | 0.80 | PPARG (0.35) | PPARGMAPTCDC25ACDC25BCDC25C | |
| SCHEMBL2107621 | 0.78 | CTRC (0.39) | PPARGMAPTCA2 | |
| SCHEMBL1080657 | 0.78 | PPARG (0.35) | PPARGMAPTCDC25ACDC25BCDC25C | |
| SCHEMBL10701592 | 0.76 | PPARG (0.35) | PPARGMAPTCDC25ACDC25BCDC25C | |
| SCHEMBL31406633 | 0.76 | PPARG (0.35) | PPARGMAPTCDC25ACDC25BCDC25C | |
| SCHEMBL31406602 | 0.74 | PPARG (0.37) | PPARGMAPTCDC25ACDC25BCDC25C | |
| SCHEMBL31406624 | 0.74 | PPARG (0.37) | PPARGMAPTCDC25ACDC25BCDC25C | |
| SCHEMBL7514099 | 0.73 | PPARG (0.33) | PPARGMAPTCDC25ACDC25BCDC25C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | claimed |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION | 2011-09-15 | — | — | US | claimed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | claimed |
| US-7125870-B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | claimed |
| US-7122560-B2 | Lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | claimed |
| US-7102008-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | claimed |
| US-7015217-B2 | Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-21 | — | — | US | claimed |
| US-6984648-B2 | Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-01-10 | — | — | US | claimed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | claimed |
| US-6927216-B2 | Cyclic sulfonyl compounds as inhibitors of metalloproteases | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-08-09 | — | — | US | claimed |
| US-20020042398-A1 | Novel lactam metalloprotease inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-11 | — | — | US | claimed |
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | claimed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | claimed |
| EP-0863885-A2 | NOVEL MACROCYCLIC COMPOUNDS AS METALLOPROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-16 | — | — | EP | claimed |
| US-5739163-A | ANTICOAGULANTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-14 | — | — | US | claimed |
| US-5691329-A | Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| US-5681951-A | REACTING PENICILLIN DERIVATIVE HAVING SULFINYL OR SULFONYL GROUP IN 2 POSITION WITH SUBSTITUTED MERCAPTAN IN PRESENCE OF SALT OF GROUP IIA OR IIIA ELEMENT | SANKYO COMPANY, LIMITED (JP) | 1997-10-28 | — | — | US | claimed |
| WO-1997018207-A2 | NOVEL MACROCYCLIC COMPOUNDS AS METALLOPROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-05-22 | — | — | WO | claimed |
| US-5563158-A | CARDIOVASCULAR DISORDERS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-08 | — | — | US | claimed |
| WO-1995018111-A1 | COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | PPARG 4804/4885MAPT 4471/4885CDC25A 605/4885 |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP14, MMP9 | PPARG 3335/4885MAPT 2590/4885CDC25A 505/4885 |
| US-20020042398-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | PPARG 4877/4885MAPT 4280/4885CDC25A 1268/4885 |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP2, MMP14 | PPARG 3325/4885MAPT 2732/4885CDC25A 351/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | PPARG 4622/4885MAPT 3487/4885CDC25A 675/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | PPARG 2440/4885MAPT 3223/4885CDC25A 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.